مباشر

FierceBiotechFrom executive assistant to chief executive: Charles River CEO Birgit Girshick on ‘the next big transition’ in the CRO industry Endpoints NewsParabilis CEO Mathai Mammen on biotech's record IPO AgilentAgilent Partners with OpenAI and BCG to Advance Artificial Intelligence in Lab Workflows - Clinical Lab Products Promega BlogPromega Builds Opportunity to Appreciate Hidden Wetland FierceBiotechADA: Novo’s Lange says ‘jury still out’ on CagriSema amid tough retatrutide comparisons BioPharma DiveEthyreal starts up with $101M and takes aim at a pair of immune diseases Clinical OMICsEngineered Salmonella Delivers Cancer-Killing Virus to Tumors Endpoints NewsNovartis and Orionis strike second molecular glue deal for $40M upfront FierceBiotechGLP-1s may combat depression by multiplying a mood-boosting gut microbe BioPharma DiveSanofi stops immune drug trial in latest research setback Endpoints NewsSonoThera raises $125M for non-viral gene therapy approach BioPharma DiveParabilis sets a record with a $670M biotech IPO

BioPharma Dive ١٠ يونيو ٢٠٢٦

AstraZeneca’s ‘extensive’ obesity drug push; $125M for ultrasound-aided genetic medicine

Newly published data convinced AstraZeneca to conduct a sprawling late-stage program for its GLP-1 pill. Elsewhere, Bausch + Lomb will lay off 119 employees and...

Newly published data convinced AstraZeneca to conduct a sprawling late-stage program for its GLP-1 pill. Elsewhere, Bausch + Lomb will lay off 119 employees and Cartesian boosted its ‘in vivo’ cell therapy capabilities.